NCT03882593

Brief Summary

Cardiopulmonary bypass (CPB) is a unique clinical scenario that results in widespread activation of the hemostatic system. Conventional CPB interferes with normal hemostasis by diluting hemostatic cells and proteins, through reinfusion of shed blood, and through activation on the bypass circuit surface of multiple systems including platelets, the kallikrein-kinin system, and fibrinolysis . Besides, deleterious effects of cardiopulmonary bypass (CPB) are partly sequelae of blood-foreign surface reactions. The arterial filter is the part of the CPB circuit where blood cells are exposed to high mechanical stress and where cellular aggregates may fasten in large quantitiesiec.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
28

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 30, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

August 30, 2018

Completed
7 months until next milestone

First Posted

Study publicly available on registry

March 20, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

March 20, 2019

Status Verified

March 1, 2019

Enrollment Period

8 months

First QC Date

August 30, 2018

Last Update Submit

March 18, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Types and characteristics of materials entrapped in the arterial line filter of cardiopulmonary bypass

    Analysis of the arterial filter from cardiopulmonay bypass circuit by scanning electron microscopy (SEM)

    At the beginning and end of cardiopulmonary bypass

  • Platelet and leukocyte gene expression analysis of arterial line filters of cardiopulmonary bypass

    Arterial filter samples from predetermined sites and sizes will be analyzed for evaluation of platelet and leukocyte gene expression in arterial filter.

    At the beginning and end of cardiopulmonary bypass

Secondary Outcomes (3)

  • Correlation between blood adhesion cells in arterial filter and coagulation tests

    At the beginning and end of cardiopulmonary bypass

  • Comparison of standard coagulation test

    At the beginning and end of cardiopulmonary bypass, Immediate postoperative; 24 hours and 48 hours after surgery

  • Comparison of free oscillation rheometry profile

    At the beginning and end of cardiopulmonary bypass

Study Arms (1)

Analysis of arterial filters during CPB

This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams

Procedure: Analysis of arterial filters after CPB

Interventions

At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.

Analysis of arterial filters during CPB

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing cardiac surgery with cardiopulmonary bypass (CPB)

You may qualify if:

  • Cardiac surgeries with extracorporeal circulation in patients older than 18 years
  • Written and signed informed consent
  • Preanesthetic assessment and preoperatory exams in accordance with study methodology

You may not qualify if:

  • Active infection;
  • Previously coagulopathy;
  • Antiplatelet therapy use until 10 days before surgery (except acetylsalicylic acid and enoxaparin that may be used in prophylactic doses until 24h before surgery);

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Incor - Heart Institute - University of Sao Paulo

São Paulo, 05403000, Brazil

RECRUITING

Related Publications (3)

  • Reynolds PS, Middleton P, McCarthy H, Spiess BD. A Comparison of a New Ultrasound-Based Whole Blood Viscoelastic Test (SEER Sonorheometry) Versus Thromboelastography in Cardiac Surgery. Anesth Analg. 2016 Dec;123(6):1400-1407. doi: 10.1213/ANE.0000000000001362.

    PMID: 27159065BACKGROUND
  • Borowiec JW, Bylock A, van der Linden J, Thelin S. Heparin coating reduces blood cell adhesion to arterial filters during coronary bypass: a clinical study. Ann Thorac Surg. 1993 Jun;55(6):1540-5. doi: 10.1016/0003-4975(93)91106-w.

    PMID: 8512409BACKGROUND
  • Galas FR, de Almeida JP, Fukushima JT, Vincent JL, Osawa EA, Zeferino S, Camara L, Guimaraes VA, Jatene MB, Hajjar LA. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1647-55. doi: 10.1016/j.jtcvs.2014.04.029. Epub 2014 Apr 18.

    PMID: 24951020BACKGROUND

MeSH Terms

Conditions

Blood Coagulation Disorders

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Anesthesiology at University São Paulo Medical School

Study Record Dates

First Submitted

August 30, 2018

First Posted

March 20, 2019

Study Start

August 30, 2018

Primary Completion

May 1, 2019

Study Completion

December 1, 2019

Last Updated

March 20, 2019

Record last verified: 2019-03

Locations